Remix Launches with $81 Million to Fund Pipeline of RNA Therapies

Rare Daily Staff

Remix Therapeutics, which is developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease, launched today with $81 million in financing.

While protein dysfunction is often the direct cause of disease, the root of that dysfunction often begins in a person’s genetic code with changes in DNA and subsequent RNA expression. Remix is designing medicines that target RNA processing to fine-tune how new RNA sequences are produced. These are small molecule therapies designed to be taken orally, allowing for therapeutic modulation throughout the body, including the central nervous system (CNS). Targeting RNA processing has the potential to address a broad range of diseases, including cancers, CNS diseases, rare diseases, and more.

Foresite Capital led the series A financing with participation from seed investors Atlas Venture and The Column Group. Additional investors joining the financing included Arch Venture and Alexandria Venture Investments.

“As we reach the limits of what is easily druggable with protein targeting therapies, reprogramming RNA processing represents an exciting new therapeutic opportunity,” said Pete Smith, co-founder, president and chief scientific officer of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. “We believe we can precisely target the cellular complexes that process RNA to address the underlying drivers of disease, working upstream of protein expression.”

Fueled by its proprietary technology platform, Remix is leveraging data analytics, high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies. The company’s approach has the unique ability to identify and target RNA processing steps to enhance or eliminate protein function, or to correct dysregulation in disease. 

“RNA has long been considered a prime therapeutic target, but its innate complexities have made it notoriously difficult to drug,” said Kevin Bitterman, chairman of the board of Remix Therapeutics and partner at Atlas Venture. “By focusing on RNA processing, the Remix team has identified a compelling way to pursue previously undruggable disease targets.”

Photo: Pete Smith, co-founder, president and chief scientific officer of Remix Therapeutics